Gastrointestinal drug development firm EA Pharma negotiated an exclusive global license to develop manufacture and market Calypso Biotechs preclinicalstage fully human antiMMP9 matrix metalloproteinase9 monoclonal antibody mAb CALY001 for inflammatory bowe...
↧